Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
Launched by ASTRAZENECA · Mar 4, 2009
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of informed consent prior to any study specific procedures.
- • A minimum of 6 months documented history of asthma according to the JGL 2006 definition
- • Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2.
- Exclusion Criteria:
- • Current or previous tobacco smokers with a history of \>= 10 pack-years
- • Use of β-blockers including eye drops
- • Clinically significant respiratory infection affecting the asthma, as judged by the investigator(s) within 4 weeks prior to visit 2
- • Intake of oral, rectal or parenteral GCS within 4 weeks prior to Visit 2
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chiyoda, Tokyo, Japan
Setagaya, Tokyo, Japan
Ichikawa, Chiba, Japan
Yokosuka, Kanagawa, Japan
Hino, Tokyo, Japan
Tachikawa, Tokyo, Japan
Patients applied
Trial Officials
Lars-Göran Carlsson, MD
Study Director
AstraZeneca R&D Lund
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials